Novartis Officially Opens $1 Billion Vaccine Manufacturing Plant in North Carolina
12/13/2011
The plant's opening marks the first change in influenza vaccine manufacturing in the United States in 50 years. Specifically, it's the first American plant capable of quickly producing pandemic and seasonal influenza vaccines using cultured animal cells rather than fertilized eggs. This new cell-based technology also may be adapted to produce large amounts of vaccines for other emerging infectious diseases.
Located on 167 acres, the Holly Springs site consists of six connected buildings comprising 430,000 square feet of manufacturing, laboratory and office space. Novartis employs about 400 colleagues here, and has plans to expand to 500 workers by year-end 2012.
"The pandemic readiness of this facility is a major milestone in national preparedness for pandemic influenza and other diseases," noted Robin Robinson, Ph.D., director of the Biomedical Advanced Research and Development Authority (BARDA) associated with HHS. Officials estimate it might be capable of producing one-fourth of the vaccine needed in America during an influenza pandemic. Relatedly, North Carolina State University is working with Novartis and BARDA to educate scientists from around the world about the plant's advanced manufacturing processes. This training should further advance efforts to stem regional and global spreading of deadly illnesses, both known and unknown.
Project Announcements
Spiritus Technologies PBC Plans Santa Fe, New Mexico, Operations
07/10/2025
Taiwan-Based Eurocharm Group Plans Kershaw County, South Carolina, Manufacturing Operations
07/10/2025
Sumitomo Electric Wiring Systems Plans Simpson County, Kentucky, Manufacturing Operations
07/10/2025
Atlantic Union Bank Expands Henrico, Virginia, Operations
07/10/2025
AssetMark Plans Charlotte, North Carolina, Operations
07/09/2025
Citigroup Plans Charlotte, North Carolina, Operations
07/09/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
In Focus: AI Is Changing Incentives Math
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
How to Choose the Right Site for Your Factory in 2025’s Volatile Landscape
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025